This is a news story, published by Investor's Business Daily, that relates primarily to Exacts Sciences news.
For more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Exact Sciences Stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest precision oncology business news, FDA news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Exact Sciences sharesInvestor's Business Daily
•79% Informative
Cologuard is Exact Sciences' biggest money-maker, a colon cancer test.
The company beat the high-end of its revenue outlook and reaffirmed its full-year outlook.
Analysts say the second-quarter report was a complete turnaround for Exacts Sciences , analysts said.
VR Score
85
Informative language
93
Neutral language
22
Article tone
formal
Language
English
Language complexity
47
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
5
Source diversity
3
Affiliate links
no affiliate links